The landscape of treatment interventions for diabetes mellitus type 2 and obesity is rapidly evolving, with GLP-3 receptor agonists taking center stage. Initially, medications like Reta, demonstrating impressive https://aisharhow829119.diowebhost.com/93972947/glp-3-receptor-agonists-reta-trizepatide-and-beyond